Adaptimmune Therapeutics PLC financial data

Symbol
ADAP on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Adaptimmune Ltd (to 3/17/2015)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 293 % -20.5%
Debt-to-equity 367 % +67.9%
Return On Assets -25 % +11.2%
Operating Margin -54.5 % +66%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.53B shares +13.1%
Common Stock, Shares, Outstanding 1.53B shares +13.5%
Entity Public Float 191M USD -21.7%
Common Stock, Value, Issued 2.08M USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 1.53B shares +38.4%
Weighted Average Number of Shares Outstanding, Diluted 1.56B shares +40.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 128M USD +2400%
Revenue from Contract with Customer, Excluding Assessed Tax 141M USD +99.9%
Research and Development Expense 147M USD +31.2%
General and Administrative Expense 71.9M USD -0.89%
Costs and Expenses 219M USD +18.6%
Operating Income (Loss) -77.1M USD +32.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -71.4M USD +19.1%
Income Tax Expense (Benefit) 1.08M USD -59.9%
Net Income (Loss) Attributable to Parent -72.5M USD +20.4%
Earnings Per Share, Basic -0.05 USD/shares +44.4%
Earnings Per Share, Diluted -0.06 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 212M USD +175%
Accounts Receivable, after Allowance for Credit Loss, Current 2.34M USD -21.4%
Other Assets, Current 3.29M USD +86.2%
Assets, Current 254M USD -3.06%
Property, Plant and Equipment, Net 45.9M USD -17.3%
Operating Lease, Right-of-Use Asset 18.2M USD -17.4%
Intangible Assets, Net (Excluding Goodwill) 996K USD +115%
Assets 322M USD -6.21%
Accounts Payable, Current 7.51M USD -48.9%
Employee-related Liabilities, Current 9.64M USD -3.82%
Accrued Liabilities, Current 30.9M USD +22.2%
Contract with Customer, Liability, Current 38.4M USD +22.3%
Liabilities, Current 82.1M USD +7.81%
Contract with Customer, Liability, Noncurrent 147M USD +23.6%
Operating Lease, Liability, Noncurrent 17.1M USD -20.8%
Other Liabilities, Noncurrent 1.44M USD +5.81%
Liabilities 225M USD +4.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.41M USD -10.3%
Retained Earnings (Accumulated Deficit) -1B USD -7.8%
Stockholders' Equity Attributable to Parent 96.3M USD -24%
Liabilities and Equity 322M USD -6.21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32M USD +14.3%
Net Cash Provided by (Used in) Financing Activities 29.2M USD +14816%
Net Cash Provided by (Used in) Investing Activities -358K USD -101%
Common Stock, Shares Authorized 2.04B shares +19.8%
Common Stock, Shares, Issued 1.53B shares +13.5%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.49M USD -129%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 215M USD +168%
Deferred Tax Assets, Valuation Allowance 295M USD +83.7%
Deferred Tax Assets, Gross 302M USD +82.2%
Operating Lease, Liability 22.4M USD -15%
Depreciation 2.77M USD +67%
Payments to Acquire Property, Plant, and Equipment 102K USD -95.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -72.8M USD +21.8%
Lessee, Operating Lease, Liability, to be Paid 26.6M USD -18%
Property, Plant and Equipment, Gross 97M USD +5.28%
Operating Lease, Liability, Current 5.29M USD +11.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.57M USD -14.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.42M USD +0.44%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -11.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.17M USD -31.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.37M USD -15.1%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.56M USD +34.3%
Additional Paid in Capital 1.1B USD +3.99%
Amortization of Intangible Assets 4.21M USD
Deferred Tax Assets, Net of Valuation Allowance 7.1M USD +34.8%
Share-based Payment Arrangement, Expense 12.4M USD -5.36%